tiprankstipranks
Intensity Therapeutics Shareholders Engage and Elect at Annual Meeting
PremiumCompany AnnouncementsIntensity Therapeutics Shareholders Engage and Elect at Annual Meeting
4M ago
Intensity Therapeutics doses first patient in Phase 3 sarcome study
Premium
The Fly
Intensity Therapeutics doses first patient in Phase 3 sarcome study
5M ago
Intensity Therapeutics files to sell 394.5K shares of common stock for holders
Premium
The Fly
Intensity Therapeutics files to sell 394.5K shares of common stock for holders
5M ago
Portage Biotech completes monetization of  Intensity Therapeutics shares
PremiumThe FlyPortage Biotech completes monetization of Intensity Therapeutics shares
8M ago
Intensity Therapeutics says cash sufficient to fund operations through 1Q25
Premium
The Fly
Intensity Therapeutics says cash sufficient to fund operations through 1Q25
8M ago
Intensity Therapeutics Unveils New Incentive Compensation Plan
Premium
Company Announcements
Intensity Therapeutics Unveils New Incentive Compensation Plan
10M ago
Intensity Therapeutics reports Q3 EPS (17c) vs (52c) last year
PremiumThe FlyIntensity Therapeutics reports Q3 EPS (17c) vs (52c) last year
1y ago
Intensity Therapeutics presents INT230-6 data at CTOSAM 2023
Premium
The Fly
Intensity Therapeutics presents INT230-6 data at CTOSAM 2023
1y ago
Intensity receives Orphan Drug Designation for three ingredients in INT230-6
Premium
The Fly
Intensity receives Orphan Drug Designation for three ingredients in INT230-6
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100